Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome plus cadonilimab for second-line advanced or metastatic gastric adenocarcinoma
ChiCTR2400090935Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome and cadonilimab in gastric adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Objective response rate and Progression-free survival. Started Oct 2024; status: recruiting.
02
Drugs
irinotecan liposomecadonilimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400090935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090935.